Kidney Res Clin Pract > Epub ahead of print
Zhang, Jia, Fu, Shi, Gao, and Xia: Bowman capsule rupture in children with myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis predicts poor renal survival

Abstract

Background

Recent developments indicated that Bowman capsule rupture (BCR) is observed in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN). We aimed to explore the relationship between BCR and clinical manifestations, pathological changes, and prognosis in children with myeloperoxidase (MPO)-AAGN.

Methods

A total of 56 children with MPO-AAGN were divided into BCR (+) and BCR (–) groups according to the status of Bowman’s capsule.

Results

After retrospective analysis of the data, 24 children (42.9%) were found to have BCR. The results showed that BCR positively correlated with intrarenal immune cell infiltrates, obsolescence and crescents in glomeruli, tubulointerstitial inflammation, tubulitis, and tubular atrophy negatively correlated with normal glomeruli and immunoglobulin G deposition in the kidney. The clinical features and kidney pathological changes were more severe in the BCR (+) group than BCR (–) group, and the renal survival rate was significantly poorer in the BCR (+) group than BCR (–) group (χ2 = 5.45, p = 0.02). Moreover, estimated glomerular filtration rate (≤15 mL/min/1.73 m2), BCR and ANCA renal risk score (ARRS) were independent risk factors for the development of end-stage kidney disease (ESKD) in children with MPO-AAGN. After combining BCR with the Berden classification and ARRS, our data suggested that the Berden classification + BCR and ARRS + BCR showed better predictive values for ESKD than those of the Berden classification and ARRS, respectively.

Conclusion

BCR is an important pathological lesion that correlates with severe clinical manifestations, pathological changes, and poor prognosis in children with MPO-AAGN.

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small and medium-sized blood vessels, with few or no immune deposits, and the appearance of circulating ANCA with specificity toward proteinase-3 (PR3) or myeloperoxidase (MPO). The spectrum of anti-neutrophil cytoplasm antibody AAV includes three clinical phenotypes: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic GPA (EGPA) [1]. AAV often affects the kidneys, the glomerulonephritis caused by AAV is called ANCA-associated glomerulonephritis (AAGN), and kidney involvement is an important factor with respect to patient morbidity and mortality.
Bowman capsule (BC) is a thick connective tissue barrier between the glomerular filtrate within the Bowman space and the interstitium. The BC is invested on its outer aspect by interstitial connective tissue, reticular fibers that contain type III collagen, and membrane-bound granular vesicles. Bowman capsule rupture (BCR) was first described in 1984, BCR was not only observed during crescent formation associated with vasculitis [2], and also found in pauci-immune glomerulonephritis [3]. In 2010, Berden et al. [4] proposed the histopathological classification dividing patients into four categories based on the proportion of normal, crescentic, and sclerotic glomeruli at renal biopsy (focal, crescentic, mixed, and sclerotic). A novel tool called the ANCA renal risk score (ARRS) was developed and validated by Brix et al. [5]. This prediction was based on three parameters: normal glomeruli, estimated glomerular filtration rate (eGFR), and interstitial fibrosis/tubular atrophy (IF/TA). However, BCR was not included in these scoring systems, also including rapidly progressive glomerulonephritis (RPGN) severity classification [6], Mayo Clinic chronicity score (MCCS) [7], and Banff scoring system [8]. Recent reports on adult patients established a better performance of the Berden classification and ARRS after the addition of BCR to these scoring systems, suggesting that the BCR lesion was independent from already described glomerular and renal tubule lesions [9]. MPO-AAGN is the predominant type in Asian, such as Chinese and Japanese, while PR3 positive is more common in Western countries [1012]. However, the effect of BCR on MPO-AAGN in children has not been explored so far, Therefore, in this study, we aimed to explore the relationship between BCR and clinical manifestations, pathological changes, and prognosis in children with MPO-AAGN.

Methods

Patient

Children (<18 years old) with biopsy-proven MPO-AAGN newly diagnosed in the Department of Pediatrics, Jinling Hospital, an Affiliated Hospital of Medical School, Nanjing University, from June 2017 to June 2022 were recruited consecutively into the study. MPO-AAGN was defined as serum MPO-ANCA positive and pauci-immune type necrotizing and/or crescentic glomerulonephritis (CrGN). Exclusion criteria were 1) PR3-ANCA positive; 2) glomerular diseases: anti-glomerular basement membrane (anti-GBM) nephritis, membranous nephropathy, Henoch-Schönlein purpura nephritis, immunoglobulin A nephropathy, and lupus nephritis (LN); 3) secondary vasculitis; 4) tumor; 5) biopsy specimens contained <10 glomeruli and follow-up duration of <6 months.
Clinical and laboratory data included demographics, clinical manifestations of AAV, serology, and urine examination. The eGFR was calculated using the modified Schwartz formula [13]. Disease activity was assessed using the pediatric vasculitis activity score (PVAS) [14]. Acute kidney injury (AKI), acute kidney disease (AKD), and chronic kidney disease (CKD) definitions were based on the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines [15]. All the data were abstracted retrospectively from the electronic medical records. The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the Ethical Committee of Jinling Hospital (No. 2019JLHGKJDWLS-177). Because of the retrospective design of the study, the need to obtain informed consent from eligible patients was waived by the Committee.

Renal histopathology

Two kidney pathologists came from the Department of Renal Pathology of Jinling Hospital evaluated all biopsies and assessed the integrity of BC and were blinded to all clinical data and analyses. Kidney tissues were stained with periodic acid-silver methenamine and evaluated by a kidney pathologist using light microscopy. BCR was defined as a discontinuity in the wall of BC in renal biopsy sections (Fig. 1; Supplementary Fig. 1, available online). Based on the status of BC, patients were divided into two groups: the BCR (+) group was defined as patients with glomeruli involved by ≥1 BCR, while those without BCR were assigned to the BCR (−) group.
Based on the Berden classification, ARRS, RPGN severity classification, and MCCS systems, the patients were divided into different types. Within a renal biopsy, infiltrates of neutrophils, eosinophils, plasma cells, and mononucleated cells (macrophages, lymphocytes) were quantified as a fraction of the area of total cortical inflammation [16]. Tubular dilatation, epithelial simplification, brush border shedding, tubular vacuolization, and casts were given a score between 0 and 4 as a percentage of the total cortical area of the biopsy (0, 0%–1%; 1, >1%–10%; 2, >10%–25%; 3, >25%–50%; and 4, >50%) [17].
We observed the distribution of tubulointerstitial inflammation and scored (score 1, ≤25%; 2, 26%–50%; and 3, >50%). The degree of tubulitis was evaluated and scored (score 1: mild, 0–9 inflammatory cells/tubules; 2: moderate, 10–14 cells/tubules; and 3: severe, 15 or more cells/tubules in the most affected region) [18]. The total renal chronicity score including global/segmental glomerular sclerosis (score 0, <10%; 1, 10%–25%; 2, 26%–50%; and 3, >50%), interstitial fibrosis (score 0, <10%; 1, 10%–25%; 2, 26%–50%; and 3, >50%); tubular atrophy (score 0, <10%; 1, 10%–25%; 2, 26%–50%; and 3, >50%), and arteriosclerosis (score 0, intimal thickening < thickness of media and 1, intimal thickening ≥ thickness of media) [16]. The extent of crescents was graded into five categories: grade 0, lesion < 10%; grade 1, 10% ≤ lesion < 25%; grade 2, 25% ≤ lesion < 50%; grade 3, 50% ≤ lesion < 75%; and grade 4, lesion ≥ 75% (lesion refer to cellular/fibrocellular) [19]. Based on the individual lesions, each biopsy was evaluated according to the Banff scoring system, and the Banff score lesions include interstitial inflammation (i), tubulitis (t), arteritis (v), glomerulitis (g), interstitial fibrosis (ci), tubular atrophy (ct), arteriolar hyalinosis (ah), peritubular capillaritis (ptc), total inflammation (ti), inflammation in areas of IF/TA (i-IF/TA), and tubulitis in areas of IF/TA (t-IF/TA) [8].

Treatments

The treatment of AAGN was based on the book of Chinese Nephrology [20]. All the patients were treated via oral prednisolone. Other treatments were determined according to clinical and pathological manifestations and disease severity, including methylprednisolone pulse therapy, cyclophosphamide, glucocorticoids, calcineurin inhibitors, hydroxychloroquine and rituximab, renal replacement therapy (RRT), and plasma exchange. There was no difference in treatment between the two groups.

Outcomes assessment

The primary endpoint of the study was the cumulative percentage of patients who developed end-stage kidney disease (ESKD) over time censored by death. ESKD was defined as the need for long-term RRT or renal transplantation. Renal survival time for each patient was computed from baseline evaluation at the time of biopsy to the last time of follow-up or the time point of reaching ESKD.

Statistical analyses

All analyses were performed using IBM SPSS version 24.0 (IBM Corp.). Continuous variables were described as mean and standard deviation or median (interquartile range [IQR]), and differences between groups were analyzed using a two-factor analysis of variance or a nonparametric test. Categorized variables were described as percentages and were analyzed using the chi-square test. The association of variables with ESKD was assessed with univariate and multivariate Cox proportional hazard regression models. The prognosis was evaluated using Kaplan-Meier curves, and the log-rank test was used to test the two curves’ differences. Spearman correlation analyses were used to analyze correlations and shown by a heatmap reflecting mean values of Spearman’s ρ, asterisks indicate p < 0.05. The r-value of >0.5 was defined as a moderate correlation. A p-value of <0.05 (two-sided) was considered significant.

Results

Baseline of demographic, clinical, and pathological characteristics

Based on clinical characteristics, the mean age was 15.28 ± 3.48 years, and 53 of 56 patients (94.6%) were diagnosed with MPA and the remainder with GPA. As presented in Table 1, the levels of C-reactive protein, serum creatinine (sCr), urinary N-acetyl-β-D-glucosidase enzyme, and neutrophil gelatinase-associated lipocalin in the BCR (+) group were higher than those in the BCR (–) group (p < 0.05), and the levels of hemoglobin, platelet, eGFR, and C3 in the BCR (+) group were lower than those in the BCR (–) group (p < 0.05 and p < 0.01). The BCR (+) group demonstrated a lower frequency of focal and higher crescentic Berden classes as compared to the BCR (–) group (p < 0.05), and the BCR (+) group had a lower percentage of ARRS low-risk and higher ARRS high-risk than the BCR (–) group (p < 0.05). Based on RPGN severity classification, the cases of grade II in the BCR (+) group were more than the BCR (–) group (p < 0.05). The extent and scores of crescents, tubulointerstitial inflammation, tubulitis, interstitial fibrosis, and tubular atrophy in the BCR (+) group were greater than the BCR (–) group (p < 0.01) (Table 1).

Correlations between Bowman capsule rupture and clinical characteristics and laboratory markers

The results of relationship between BCR and clinical and laboratory features were shown in Fig. 1. BCR positively correlated with the manifestations of AKI, AKD, lung injury, pneumorrhagia, and thrombus (r = 0.52, p < 0.001; r = 0.499, p < 0.001; r = 0.60, p < 0.001; r = 0.41, p = 0.002; and r = 0.27, p = 0.045; respectively), and positively correlated with levels of white blood cells, sCr, and PVAS (r = 0.32, p = 0.02; r = 0.27, p = 0.045; and r = 0.39, p = 0.003; respectively), and negatively correlated with eGFR (r = –0.27, p = 0.04). Above them, BCR positively moderately correlated with AKI, AKD, and lung injury.

Correlations between Bowman capsule rupture and renal pathological changes

Considering that BCR was a special pathological lesion, we analyzed the relationship between BCR and renal pathological changes. We found that BCR positively correlated with intrarenal neutrophils, mononuclear cells, plasma cells, and eosinophils infiltrates (r = 0.62, p < 0.001; r = 0.60, p < 0.001; r = 0.44, p = 0.001; and r = 0.28, p = 0.04; respectively) (Fig. 2A). BCR positively correlated with glomerular obsolescence and crescent, tubulointerstitial inflammation score, tubulitis score, tubular atrophy score, epithelial simplification, tubular dilation, tubular vacuolization, and granular casts (r = 0.34, p = 0.01; r = 0.50, p < 0.001; r = 0.56, p < 0.001; r = 0.41, p = 0.002; r = 0.31, p = 0.02; r = 0.55, p < 0.001; r = 0.41, p = 0.002; r = 0.31, p = 0.02; and r = 0.31, p = 0.02; respectively), and negatively correlated with normal glomeruli and immunoglobulin G (IgG) deposition (r = –0.29, p = 0.03 and r = –0.41, p = 0.002; respectively) (Fig. 2B). We also analyzed the relationship between BCR and Banff score system, and the results showed that BCR positively correlated with interstitial inflammation (i), tubulitis (t), tubular atrophy (ct), total inflammation (ti), and i-IF/TA (r = 0.50, p < 0.001; r = 0.41, p = 0.002; r = 0.31, p = 0.02; r = 0.43, p = 0.001; and r = 0.40, p = 0.003; respectively). The above results suggested that BCR positively moderately correlated with intrarenal neutrophils and mononuclear cell infiltrates, crescent, tubulointerstitial inflammation score, epithelial simplification, and interstitial inflammation (i) (Fig. 2C).

Correlations between Bowman capsule rupture and clinical and pathological scoring system

BCR positively correlated with mixed and crescentic groups in the Berden classification, ARRS medium-risk and high-risk groups, and MCCS minimal group (r = 0.27, p = 0.045; r = 0.45, p < 0.001; r = 0.27, p = 0.045; r = 0.37, p = 0.005; and r = 0.27, p = 0.046; respectively), and negatively correlated with focal group of the Berden classification and ARRS low-risk group (r = –0.45, p < 0.001 and r = –0.52, p < 0.001; respectively). Of which, BCR negatively moderately correlated with ARRS low-risk group (Fig. 2D).

Survival analysis and risk factor

The median follow-up period was 31.98 months (IQR, 16.64–45.51 months). During the observational period, 12 children (21.4%) progressed to ESKD, with significantly more patients in the BCR (+) group than BCR (–) group (p < 0.05). There were three deaths (5.4%), including two cases in BCR (+) group and one case in BCR (–) group. The causes of death were interstitial pneumonia (n = 2) and sepsis (n = 1). We analyzed renal survival according to BCR. Our results showed that the estimated renal survival at 1 and 3 years in the BCR (+) group were 100% and 77.9%, respectively, and the renal survival was 100% at both 1 and 3 years in the BCR (–) group. The renal survival rate in the BCR (+) group was significantly poorer than the BCR (–) group (χ2 = 5.45, p = 0.02) (Fig. 3A); however, there was a numerical but not statistical difference in ESKD-free survival between two groups (χ2 = 0.51, p = 0.47) (Fig. 3B). The multivariate Cox regression analysis showed that eGFR of ≤15 mL/min/1.73 m2 (hazard ratio [HR], 1.71; 95% confidence interval [CI], 0.87–3.33; p = 0.02), BCR (HR, 11.28; 95% CI, 2.64–21.17; p = 0.003), and ARRS (HR, 17.14; 95% CI, 6.88–40.52; p = 0.009) were independent risk factors for the development of ESKD in children with MPO-AAGN (Table 2). And multivariate logistic regression analysis showed that BCR was associated with neutrophils and plasma cell infiltration, tubulointerstitial inflammation (Table 3).

Comparison of predictive value between the Berden classification, antineutrophil cytoplasmic antibody renal risk score, and Bowman capsule rupture

The area under the curve for ESKD prediction at the end of follow-up of the Berden classification, ARRS, and BCR were 0.60 (p = 0.28), 0.79 (p = 0.002), and 0.69 (p = 0.04), respectively. ARRS showed better predictive value for ESKD than those of the Berden classification (p = 0.004) (Fig. 4A; Supplementary Fig. 2, available online). After combining BCR with ARRS and the Berden classification, they show better predictive values. The Berden classification + BCR showed better predictive value for ESKD than those of the Berden classification (0.79 vs. 0.60, p = 0.004) (Fig. 4B), ARRS + BCR showed better predictive value for ESKD than those of the ARRS (0.94 vs. 0.79, p = 0.001) (Fig. 4C), and ARRS + BCR showed better predictive value for ESKD than those of the Berden classification + BCR (0.94 vs. 0.79, p = 0.002) (Fig. 4D).

Discussion

BCR was first reported more than 30 years ago, and only a few case reports have described its presence in diseased kidneys to date. Previous research showed that BCR was present in 21% to 65% of adult patients with AAGN [2125]. The percentage of BCR in our series of AAGN children was 42.9%, which was consistent with the data in previous literature.
BC was implicated in functionally isolating potential immune effectors thereby preventing injury to the glomerulus, and an intact BC prevents inflammatory cells from gaining access to the glomerular space. However, once BC was breached, inflammatory cells could access the glomerular space in CrGN with BCR enabling direct pathological interaction between both compartments [26]. When renal inflammation leads to the destruction of glomerular capillaries and the release of proinflammatory cytokines and chemokines into the BC, parietal epithelial cells proliferate and build crescents [27]. When BC was normal, vascular injury causing ruptures in the GBM that triggered plasmatic coagulation within BC, drove hyperplasia of parietal epithelial cells and the formation of crescent. Furthermore, immune cell infiltrates in AAGN were found to influence renal outcomes [28]. In addition to AAGN, BCR is also present in immune complex-mediated CrGN, anti-GBM CrGN, and LN [2325,29]. Therefore, we suspected that the formation of BCR may be associated with renal inflammation, immune cell infiltration, and renal prognosis in children with MPO-AAGN.
To clarify the role of BCR in AAGN, we evaluated differences in clinical and laboratory manifestations and renal histopathology changes between the BCR (+) and BCR (–) groups. Our results indicated that the clinical features and kidney involvement were more severe in the BCR (+) group. The renal survival rate was significantly poorer in the BCR (+) group than in the BCR (–) group.
The relationship between BCR and renal pathological changes in the kidney had rarely been reported. Recent studies have shown that BCR links glomerular damage to tubulointerstitial inflammation in a considerable subset of patients with AAGN [9,21,30]. Hakroush and Tampe [30] found that BCR was associated with tubulointerstitial inflammation containing infiltrates of neutrophils, eosinophils, and plasma cells. A study on LN showed that BCR was correlated with the levels of crescents, tubular atrophy, and interstitial fibrosis [29]. To our knowledge, the relationship between BCR and renal pathological changes lesions in children with MPO-AAGN has not been reported. In our study, as suggested by the results from the MPO-AAGN children, the BCR is positively associated with intrarenal immune cells infiltration, glomerular obsolescence and crescents, tubulointerstitial inflammation, tubulitis, tubular atrophy, and inflammatory and tubular lesions in the Banff score system, and negatively correlated with normal glomeruli and IgG deposition in the kidney. However, Hakroush and Tampe [31] demonstrated that an association between tubulointerstitial inflammation and BCR was specifically observed in PR3-AAGN and was not observed in adult with MPO-AAGN. These findings indicated that the renal pathology of AAGN in adults and children is different, and further research on the mechanism is needed. Multivariate logistic regression analysis confirmed that BCR was associated with neutrophil and plasma cell infiltration, and tubulointerstitial inflammation, which provides a theoretical reference for research on the BCR formation mechanism.
For almost two decades, constant effort has been made to stratify ESKD risk in AAGN. We demonstrated that BCR has independently been associated with poor renal outcomes in children with MPO-AAGN. Recent studies have demonstrated the good discrimination of the Berden classification and ARRS, and the relationship between ARRS and BCR as well as the effect of BCR on renal prognosis has gradually attracted the attention of clinicians. L’Imperio and Pagni [32] showed that arteritis was correlated with evidence of BCR in AAV, which suggested a complementary role for these two features in improving the predictive performance of the ARRS. Duan et al. [29] suggested that it correlates with severe clinical manifestations, pathological changes, and poor prognosis in patients with LN. Furthermore, we incorporated BCR into the two models that permitted the identification of MPO-AAGN patients who could benefit from that, with better sensitivity and specificity. Our data suggested that the Berden classification + BCR and ARRS + BCR showed better predictive values for ESKD than those of the Berden classification and ARRS, respectively. And ARRS + BCR showed better predictive value for ESKD than those of the Berden classification + BCR. These findings illustrated that indications of BCR need to be clarified, and it would be very interesting to assess its value in other cohorts with AAGN and CrGN.
Our study also had certain limitations. First, we excluded children with known PR3-AAGN, so our results are not generalizable to that subset of children. Second, due to the limited number of patients, it was difficult to determine the effect of drugs on BCR. Finally, this was a single-center retrospective observational analysis, and it was difficult to control for all factors that may affect renal survivorship.
Our study represents a further step in the description of the relationship between BCR and renal damage. This was the first study to describe the relationship between BCR and MPO-AAGN in children. We show that BCR was frequent in children with MPO-AAGN and was observed in a subset of renal biopsies in our single-center cohort. Additionally, BCR was an independent risk factor for the development of ESKD. Furthermore, a better performance of the Berden classification and ARRS were observed after the implementation of BCR to the classification systems.

Notes

Conflicts of interest

All authors have no conflicts of interest to declare.

Funding

This study was supported by the Postdoctoral Fund of Jiangsu Province (2018K089B, category A), China Postdoctoral Foundation (2018M643888), and Natural Science Foundation & Youth Fund Plan of Jiangsu Province (BK20190251).

Data sharing statement

The data presented in this study are available on request from the corresponding author.

Authors’ contributions

Conceptualization: CG

Data curation, Formal analysis: PZ, LJ

Investigation: MF, KS

Methodology, Funding acquisition, Supervision: ZX

Writing–original draft: PZ, LJ

Writing–review & editing: all authors

All authors read and approved the final manuscript.

Supplementary Materials

Supplementary data are available at Kidney Research and Clinical Practice online (https://doi.org/10.23876/j.krcp.23.051).

Figure 1.

Associations of BCR with clinical manifestations and laboratory parameters in children with MPO-AAGN.

(A) BCR positively correlated with the manifestations of AKI, AKD, lung injury, pneumorrhagia, and thrombus in children with MPO-AAGN. (B) BCR positively correlated with levels of WBC, sCr, and PVAS, and negatively correlated with eGFR in children with MPO-AAGN.
AAGN, antineutrophil cytoplasmic antibody-associated glomerulonephritis; AKD, acute kidney disease; AKI, acute kidney injury; BCR, Bowman capsule rupture; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; IL-6, interleukin-6; Ig, immunoglobulin; MPO, myeloperoxidase; NAG, N-acetyl-β-D-glucosidase; NGAL, neutrophil gelatinase-associated lipocalin; PCT, procalcitonin; PLT, platelet; PVAS, pediatric vasculitis activity score; RGP, renal growth peptide; sCr, serum creatinine; WBC, white blood cells.
*p < 0.05, **p < 0.01.
j-krcp-23-051f1.jpg
Figure 2.

Correlations of BCR with renal histopathological features and classification in patients with glomerulonephritis.

(A) BCR positively correlated with intrarenal neutrophils, mononuclear cells, plasma cells, and eosinophils infiltrates. (B) BCR positively correlated with glomerular obsolescence and crescent, tubulointerstitial inflammation score, tubulitis score, tubular atrophy score, epithelial simplification, tubular dilation, tubular vacuolization, and granular casts, and negatively correlated with normal glomeruli and IgG deposition. (C) BCR positively correlated with interstitial inflammation (i), tubulitis (t), tubular atrophy (ct), total inflammation (ti), and i-IF/TA. (D) BCR positively correlated with mixed and crescentic groups in the Berden classification, ARRS medium-risk and high-risk groups, and MCCS minimal group, and negatively correlated with the focal group of the Berden classification and ARRS low-risk group.
ARRS, antineutrophil cytoplasmic antibody renal risk score; BCR, Bowman capsule rupture; i-IF/TA, inflammation in areas of interstitial fibrosis/tubular atrophy; Ig, immunoglobulin; MCCS, Mayo Clinic chronicity score; RBC, red blood cells; t-IF/TA, tubulitis in areas of interstitial fibrosis/tubular atrophy.
*p < 0.05, **p < 0.01.
j-krcp-23-051f2.jpg
Figure 3.

Renal survival analysis in ESKD cohort based on BCR.

(A) Renal survival in the ESKD cohort according to BCR. The renal survival rate in BCR (+) group was significantly poorer than BCR (–) group (p = 0.02). (B) Survival free of ESKD according to BCR. There was a numerical but not statistical difference in ESKD-free survival between the two groups (p = 0.47).
BCR, Bowman capsule rupture; ESKD, end-stage kidney disease.
j-krcp-23-051f3.jpg
Figure 4.

Comparative ROC analysis of renal outcomes using various classification and grading systems in ESKD.

(A) ROC curve of renal outcomes using the ARRS, Berden classification, and RPGN grading system. ARRS showed better predictive value for ESKD than those of the Berden classification (p = 0.004). (B) The comparison between Berden classification and Berden classification + BCR of ROC curve. Berden classification + BCR showed better predictive value for ESKD than those of the Berden classification (p = 0.004). (C) The comparison between ARRS and ARRS + BCR of ROC curve. ARRS + BCR showed better predictive value for ESKD than those of the ARRS (p = 0.001). (D) The comparison between Berden classification + BCR and ARRS + BCR of ROC curve. ARRS + BCR showed better predictive value for ESKD than those of the Berden classification + BCR (p = 0.002).
ARRS, antineutrophil cytoplasmic antibody renal risk score; BCR, Bowman capsule rupture; ESKD, end-stage kidney disease; ROC curve, receiver operating characteristic curve; RPGN, rapidly progressive glomerulonephritis.
j-krcp-23-051f4.jpg
Table 1.
Baseline demographic, clinical, and pathological features of patients in the BCR (+) and BCR (–) groups
Variable Total BCR (+) group BCR (–) group p-value
No. of patients 56 24 32
Age (yr) 15.28 ± 3.48 14.84 ± 3.27 15.79 ± 3.68 0.22
Sex, male:female 11:45 5:19 6:26 0.85
CRP (mg/L) 9.18 (24.58–34.06) 12.24 (28.13–42.32) 7.55 (18.36–29.71) 0.003
Hemoglobin (g/L) 76.84 ± 18.46 68.55 ± 20.32 81.78 ± 24.16 0.04
Platelet (×109/L) 97.26 ± 26.54 85.63 ± 19.17 112.43 ± 28.05 0.04
Serum albumin (g/dL) 155.87 ± 43.18 175.45 ± 58.92 122.71 ± 38.96 0.04
eGFR (mL/min/1.73 m2) 40.55 (28.35–57.89) 34.05 (22.75–52.55) 52.75 (37.05–67.25) 0.007
C3 (g/L) 0.72 (0.56–1.14) 0.67 (0.45–1.02) 0.84 (0.66–1.33) 0.01
C4 (g/L) 0.18 ± 0.03 0.20 ± 0.04 0.19 ± 0.03 0.54
24-hr urinary protein (mg/kg/24 hr) 36.25 (20.75–42.05) 40.25 (25.75–53.05) 31.05 (23.25–45.75) 0.21
Urinary NAG enzyme (U/g Cr) 30.85 (20.18–52.27) 37.05 (28.34–56.42) 26.32 (18.75–48.19) 0.02
Urinary RBP (mg/L) 0.83 (0.56–2.87) 0.87 (0.45–3.13) 0.78 (0.56–2.55) 0.36
Urinary NGAL (μg/L) 106.44 (51.34–195.59) 128.83 (64.29–212.75) 84.72 (43.62–165.39) 0.02
Pulmonary involvement 10 (17.9) 6 (25.0) 5 (15.6) 0.38
Hematuria 51 (91.1) 21 (87.5) 30 (93.8) 0.42
PVAS score 15.05 (11.75–18.75) 16.05 (9.75–20.75) 13.75 (13.05–17.25) 0.63
Obsolescence 3.87 (1.25–8.59) 3.66 (1.37–9.25) 3.95 (1.18–7.57) 0.42
Crescent 38.53 (27.65–53.47) 46.25 (31.42–66.28) 22.30 (23.16–42.65) <0.001
Sclerosis 23.28 (18.32–42.57) 38.45 (25.38–51.65) 17.65 (12.36–36.25) 0.002
Tubulointerstitial inflammation score 1.65 (1.13–2.24) 1.77 (1.26–2.73) 1.35 (1.05–1.75) 0.02
Tubulitis score 1.48 (1.20–2.38) 1.82 (1.35–2.56) 1.33 (1.12–2.25) 0.04
Total renal chronicity score 1.32 (1.24–2.16) 1.35 (1.32–2.57) 1.33 (1.20–2.05) 0.25
Interstitial fibrosis score 2.15 (1.36–2.82) 2.38 (1.55–2.95) 1.85 (1.29–2.67) 0.03
Tubular atrophy score 1.58 (1.21–2.75) 1.64 (1.44–2.83) 1.43 (1.14–2.65) 0.03
Epithelial simplification 0.65 (0.42–0.88) 0.57 (0.46–0.84) 0.68 (0.39–0.92) 0.22
Tubular dilation 0.26 (0.15–0.43) 0.28 (0.17–0.45) 0.25 (0.13–0.42) 0.52
Brush border shedding 0.34 (0.22–0.55) 0.31 (0.25–0.58) 0.36 (0.18–0.53) 0.31
Berden classification
 Focal 14 (25.0) 2 (8.3) 12 (37.5) 0.01
 Crescentic 19 (33.9) 12 (50.0) 7 (21.9) 0.03
 Sclerotic 10 (17.9) 5 (20.8) 5 (15.6) 0.62
 Mixed 13 (23.2) 5 (20.8) 8 (25.0) 0.72
ARRS
 Low-risk 25 (44.6) 7 (29.2) 18 (56.3) 0.04
 Medium-risk 19 (33.9) 8 (33.3) 11 (34.4) 0.94
 High-risk 12 (21.4) 9 (37.5) 3 (9.4) 0.01
RPGN severity classification
 Grade I 14 (26.8) 3 (12.5) 11 (34.4) 0.06
 Grade II 33 (42.9) 14 (58.3) 19 (59.4) 0.94
 Grade II 9 (30.4) 7 (29.2) 2 (6.3) 0.02
 Grade IV 0 (0) 0 (0) 0 (0) -
MCCS
 Minimal 34 (60.7) 16 (66.7) 18 (56.3) 0.43
 Mild 18 (32.1) 7 (29.2) 11 (34.4) 0.68
 Moderate 3 (5.4) 1 (4.2) 2 (6.3) 0.73
 Severe 1 (1.8) 0 (0) 1 (1.8) -
ESKD 12 (21.4) 9 (37.5) 3 (9.4) 0.01
Dead 3 (5.4) 2 (8.3) 1 (3.1) 0.39

Data are expressed as number only, mean ± standard deviation, median (interquartile range), or number (%).

ARRS, antineutrophil cytoplasmic antibody renal risk score; BCR, Bowman capsule rupture; Cr, creatinine; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; MCCS, Mayo Clinic chronicity score; NAG, N-acetyl-β-D-glucosidase; NGAL, neutrophil gelatinase-associated lipocalin; PVAS, pediatric vasculitis activity score; RBP, retinol-binding protein; RPGN, rapidly progressive glomerulonephritis.

Table 2.
Cox regression analysis on the influencing factors of children with MPO-AAGN
Variable Univariate analysis
Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
eGFR (≤15 mL/min/1.73 m2) 1.76 (0.97–3.55) 0.02 1.71 (0.87–3.33) 0.02
IF/TA 0.75 (0.17–7.21) 0.83
Crescent (≥50%) 6.33 (1.53–12.21) 0.07
BCR 12.44 (2.94–23.26) 0.001 11.28 (2.64–21.17) 0.003
ARRS 18.43 (7.32–42.34) 0.006 17.14 (6.88–40.52) 0.009

AAGN, antineutrophil cytoplasmic antibody-associated glomerulonephritis; ARRS, antineutrophil cytoplasmic antibody renal risk score; BCR, Bowman capsule rupture; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IF/TA, interstitial fibrosis/tubular atrophy; MPO, myeloperoxidase.

Table 3.
Logistic regression analysis for BCR in children with MPO-AAGN
Variable Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Neutrophils 3.50 (1.48–8.15) 0.03 3.32 (1.27–8.02) 0.04
Mononuclear cells 1.13 (0.99–1.13) 0.08
Plasma cells 10.27 (1.30–42.02) 0.03 10.07 (1.24–40.98) 0.04
Eosinophils 13.08 (7.29–86.37) 0.11
Tubulointerstitial inflammation 1.13 (1.03–1.25) 0.01 1.04 (0.92–1.22) 0.02
Tubulitis 21.23 (0.43–164.65) 0.15

AAGN, antineutrophil cytoplasmic antibody-associated glomerulonephritis; BCR, Bowman capsule rupture; CI, confidence interval; HR, hazard ratio; MPO, myeloperoxidase.

References

1. Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 2019;15:91–101.
2. Morel-Maroger Striker L, Killen PD, Chi E, Striker GE. The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 1984;51:181–192.
crossref pmid pdf
3. Al-Hussain T, Asiri S, Amer S, Al Mana H, Akhtar M. Patterns of glomerulonephritis with crescents: experience at a tertiary medical center in Saudi Arabia. Saudi J Kidney Dis Transpl 2017;28:532–537.
pmid
4. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628–1636.
crossref pmid
5. Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 2018;94:1177–1188.
crossref pmid
6. Koyama A, Yamagata K, Makino H, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol 2009;13:633–650.
crossref pmid
7. Sethi S, D’Agati VD, Nast CC, et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int 2017;91:787–789.
crossref pmid pdf
8. Roufosse C, Simmonds N, Clahsen-van Groningen M, et al. A 2018 reference guide to the Banff Classification of Renal Allograft Pathology. Transplantation 2018;102:1795–1814.
crossref pmid
9. L’Imperio V, Vischini G, Pagni F, Ferraro PM. Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications. Ann Rheum Dis 2022;81:e95.
crossref pmid pmc
10. An XN, Wei ZN, Yao XY, et al. Evaluating renal outcome of ANCA-associated renal vasculitis: comparative study of two histopathological scoring systems. Clin Exp Rheumatol 2021;39 Suppl 129:39–45.
crossref pmid
11. Saito M, Saito A, Abe F, et al. Evaluation of a newly proposed renal risk score for Japanese patients with ANCA-associated glomerulonephritis. Clin Exp Nephrol 2022;26:760–769.
crossref pmid
12. Hong Y, Shi P, Liu X, et al. Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study. Clin Rheumatol 2019;38:1665–1673.
crossref pmid pdf
13. Calatroni M, Consonni F, Allinovi M, et al. Prognostic factors and long-term outcome with ANCA-associated kidney vasculitis in childhood. Clin J Am Soc Nephrol 2021;16:1043–1051.
crossref pmid pdf
14. Dolezalova P, Price-Kuehne FE, Özen S, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2013;72:1628–1633.
crossref pmid pmc
15. Levey AS. Defining AKD: the spectrum of AKI, AKD, and CKD. Nephron 2022;146:302–305.
crossref pmid
16. Hakroush S, Tampe D, Ströbel P, Korsten P, Tampe B. Comparative histological subtyping of immune cell infiltrates in MPO-ANCA and PR3-ANCA glomerulonephritis. Front Immunol 2021;12:737708.
crossref pmid pdf
17. Pieters TT, Falke LL, Nguyen TQ, et al. Histological characteristics of acute tubular injury during delayed graft function predict renal function after renal transplantation. Physiol Rep 2019;7:e14000.
crossref pmid pmc
18. Masuzawa N, Nishimura A, Mihara Y, Tamagaki K, Konishi E. Clinicopathological analysis of ANCA-associated glomerulonephritis focusing on plasma cell infiltrate. Clin Exp Nephrol 2019;23:1373–1381.
crossref pmid pmc pdf
19. Nakakita T, Akiyama K, Karasawa K, et al. Analysis of various types of glomerulonephritis with crescents at a single center. Int J Nephrol 2022;2022:1749548.
crossref pmid pdf
20. Li L, Liu Z. Chinese nephrology. People's Military Medical Publishing House; 2008.
crossref pmid pmc pdf
21. Hakroush S, Tampe B. Correspondence on ‘Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’. Ann Rheum Dis 2023;82:e125.
crossref pmid
22. Lin W, Shen C, Zhong Y, et al. Glomerular immune deposition in MPO-ANCA associated glomerulonephritis is associated with poor renal survival. Front Immunol 2021;12:625672.
crossref pmid pmc
23. Hu X, Shen C, Meng T, et al. Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients. Front Immunol 2022;13:991469.
crossref pmid pmc
24. Gupta A, Agrawal V, Kaul A, et al. Etiological spectrum and clinical features in 215 patients of crescentic glomerulonephritis: is it different in India? Indian J Nephrol 2021;31:157–162.
crossref pmid pmc
25. Gupta R, Singh L, Sharma A, Bagga A, Agarwal SK, Dinda AK. Crescentic glomerulonephritis: a clinical and histomorphological analysis of 46 cases. Indian J Pathol Microbiol 2011;54:497–500.
crossref pmid
26. Baier E, Kluge IA, Hakroush S, Tampe D, Tampe B. Leukocyturia and hematuria enable non-invasive differentiation of Bowman’s capsule rupture severity in PR3-ANCA glomerulonephritis. J Nephrol 2023;36:799–808.
crossref pmid pdf
27. Linke A, Tiegs G, Neumann K. Pathogenic T-cell responses in immune-mediated glomerulonephritis. Cells 2022;11:1625.
crossref pmid pmc
28. Chen A, Lee K, D’Agati VD, et al. Bowman’s capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells. J Clin Invest 2018;128:3413–3424.
crossref pmid pmc
29. Duan T, Zhu X, Zhao Q, et al. Association of Bowman’s capsule rupture with prognosis in patients with lupus nephritis. J Nephrol 2022;35:1193–1204.
crossref pmid pdf
30. Hakroush S, Tampe D, Korsten P, Ströbel P, Tampe B. Bowman’s capsule rupture links glomerular damage to tubulointerstitial inflammation in ANCA-associated glomerulonephritis. Clin Exp Rheumatol 2021;39 Suppl 129:27–31.
crossref pmid
31. Hakroush S, Tampe B. Neutrophils associate with Bowman’s capsule rupture specifically in PR3-ANCA glomerulonephritis. J Nephrol 2022;35:1177–1183.
crossref pmid pdf
32. L’Imperio V, Pagni F. Unveiling the role of additional histological parameters in ANCA-associated vasculitis. J Am Soc Nephrol 2022;33:1226–1227.
crossref pmid pmc


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#301, (Miseung Bldg.) 23, Apgujenog-ro 30-gil, Gangnam-gu, Seoul 06022, Korea
Tel: +82-2-3486-8736    Fax: +82-2-3486-8737    E-mail: registry@ksn.or.kr                

Copyright © 2024 by The Korean Society of Nephrology.

Developed in M2PI

Close layer